“…Previous systematic reviews, including one meta-analysis, have also concluded that ERAS programmes conferred improved mortality alongside a reduction in hospital LoS and postoperative complication rates (10) [which in turn are an independent determinant of long term survival (11)]. Longer-term benefits for patients and the health economic advantages of ERAS are also beginning to emerge as established ERAS programmes begin to produce 5and 10-year follow-up data (7,12). In cancer surgery, by facilitating a more rapid recovery and return to baseline function, ERAS programmes may permit earlier treatment with adjuvant cancer therapies-potentially conferring an improvement in oncological outcomes and survival (13).…”